COMMUNIQUÉS West-GlobeNewswire
-
Revagenix Doses First Participant in Phase 1 Trial of Rev-56, an Inhaled Therapy for Non-CF Bronchiectasis
27/07/2026 -
Landmark 10-Year Study Strengthens Long-Term Evidence Supporting Focal Therapy
27/07/2026 -
SafeSpace Global Announces AI-Powered Senior Living Safety Pilot with Blakeford at Green Hills
27/07/2026 -
Intuitive Collaborates with Deion “Coach Prime” Sanders to Raise Patient Awareness of Surgical Options
27/07/2026 -
CurePSP Invests in the Next Generation of PSP and CBD Researchers with Student Fellowship Awards
27/07/2026 -
Rose Hill Life Sciences Appoints Jama Pitman as Chief Executive Officer
27/07/2026 -
Assisting Hands Home Care Frisco Trains Caregivers in Stroke Recovery, Brings Post-Stroke Education to North Texas Families
27/07/2026 -
Oktopi secures follow-on funding to expand OktoPilot's AI-informed capabilities, building on the inaugural global health grant
27/07/2026 -
Applied Biologics Announces Extension of Longstanding System-Wide Agreement With Providence Health & Services for XWRAP®
27/07/2026 -
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction
27/07/2026 -
ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division
27/07/2026 -
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
27/07/2026 -
Legend Biotech Announces CEO Transition
27/07/2026 -
The Ensign Group Reports Second Quarter 2026 Results
27/07/2026 -
CorVel Corporation to Host Live Earnings Release Webcast
27/07/2026 -
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
27/07/2026 -
Vireo Growth Inc. to Acquire Planet 13 Holdings Inc.
27/07/2026 -
Novo Nordisk A/S - share repurchase programme
27/07/2026 -
InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
27/07/2026
Pages